You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股業績》吉利德(GILD)愛滋及新冠藥銷售勝預期 惟純利大減99%
阿思達克 04-29 11:12
美國生物製藥公司吉利德科學(GILD.US)公布首季業績。季度純利1,900萬美元,按年大減99%。每股季度攤薄純利2美仙,經調整後為2.12美元,高於市場預期的1.81美元。季度收入65.9億美元,按年升3%,高於市場預期的62.7億美元。 公司愛滋病藥物銷售按年升2%至37億美元,略高於市場預期。新冠藥瑞德西韋銷售按年升5%至15億美元,高於市場預期的11.5億美元。 公司因應癌症藥Trodelvy測試結果,就2020年收購Immunomedics作出27億美元研發減值。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account